Skip to main content
Top
Published in: Medical Oncology 1/2009

01-03-2009 | Original Paper

Significance of p53 and CD31 in astrogliomas

Authors: Abdul-Zaher M. Khattab, Magdy I. Ahmed, Mohamed A. Fouad, Waleed A. Essa

Published in: Medical Oncology | Issue 1/2009

Login to get access

Abstract

Background Astrogliomas are the most common primary brain tumor. Its progression is the result of activation of oncogenes, inactivation of tumor suppressor genes (TSGs), and expression of various growth factors. The angiogenesis and p53 in astrogliomas play an important role in its grading, treatment strategies, and hence its clinical outcome. Objectives To analyze the frequency of presentation and the possible co-expression of p53 and angiogenesis marker (CD31) and their clinical implications in astrogliomas. Material and methods This retrograde study included 45 cases with astrocytomas in the form of paraffin blocks. Sections were stained with hematoxylin and eosin to determine the type and histological grade according to WHO (2007) classification of CNS tumors. Immunostaining was done using anti p53 and CD31 and the results were measured as labeling index (LI) using image analyzer system CAS-200. Results Both p53 and CD31 expressions were correlated well with the histopathological grades of different subtypes of astrogliomas with good discrimination between low and high grades. Overall, a highly significant statistical correlation was observed between the grades of astrocytomas and the p53 and CD31 labeling indices. The expressions of p53 and CD31 were markedly increased in glioblastoma multiforme (GBM) with mean values (59.7 ± 13.5) (P = 0.0001) and (40.7 ± 8.9) (P = 0.001), respectively. Obviously, these observations demonstrate that the co-expression and increased levels of p53 and CD31 in astrogliomas are increasing as the tumor grade is increasing. Conclusion The estimation of p53 and CD31 could be used as good tools to assess the grade, prognosis, and aggressiveness of the astroglial tumors. Thus, the two markers can be used as adjunct to the diagnosis and stratification of the high grade from the low-grade intrinsic brain astrogliomas.
Literature
1.
go back to reference Grant R. Overview: brain tumor diagnosis and management. Royal College of Physicians Guidelines. J Neurol Neurosurg Psychiatry. 2004;75(2):ii18–23.PubMedCrossRef Grant R. Overview: brain tumor diagnosis and management. Royal College of Physicians Guidelines. J Neurol Neurosurg Psychiatry. 2004;75(2):ii18–23.PubMedCrossRef
2.
go back to reference Broniscer A, et al. Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J Clin Oncol. 2007;20(6):682–9.CrossRef Broniscer A, et al. Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J Clin Oncol. 2007;20(6):682–9.CrossRef
3.
go back to reference El-Bolkainy MN, Nouh A, El-Bolkainy TN. Epidemiology of cancer. In: Topographic pathology of cancer. Tumors of the central nervous system, 3rd ed., chap. 15, 2005. p. 135–46. El-Bolkainy MN, Nouh A, El-Bolkainy TN. Epidemiology of cancer. In: Topographic pathology of cancer. Tumors of the central nervous system, 3rd ed., chap. 15, 2005. p. 135–46.
4.
go back to reference Avninder S, et al. Gemistocytic astrocytomas: histomorphology, proliferative potential and genetic alterations—a study of 32 cases. J Neurooncol. 2006;78(2):123–7.PubMedCrossRef Avninder S, et al. Gemistocytic astrocytomas: histomorphology, proliferative potential and genetic alterations—a study of 32 cases. J Neurooncol. 2006;78(2):123–7.PubMedCrossRef
5.
go back to reference Phatak P, Selvi SK, Divya T, Hegde AS, Hegde S, Somasundaram K. Alterations in tumor suppressor gene p53 in human gliomas from Indian patients. J Biosci. 2002;27(7):673–8.PubMedCrossRef Phatak P, Selvi SK, Divya T, Hegde AS, Hegde S, Somasundaram K. Alterations in tumor suppressor gene p53 in human gliomas from Indian patients. J Biosci. 2002;27(7):673–8.PubMedCrossRef
6.
go back to reference Rodriguez-Pereira C, et al. Analysis of 2 antiapoptotic factors in gliomas: bcl-2 overexpression and p53 mutations. Arch Pathol Lab Med. 2001;125(2):218–23.PubMed Rodriguez-Pereira C, et al. Analysis of 2 antiapoptotic factors in gliomas: bcl-2 overexpression and p53 mutations. Arch Pathol Lab Med. 2001;125(2):218–23.PubMed
7.
go back to reference Afshar G, et al. Radiation-induced caspase-8 mediates p53-independent apoptosis in glioma cells. Cancer Res. 2006;66(8):4223–32.PubMedCrossRef Afshar G, et al. Radiation-induced caspase-8 mediates p53-independent apoptosis in glioma cells. Cancer Res. 2006;66(8):4223–32.PubMedCrossRef
8.
go back to reference Shu KX, Li B, Wu LX. The p53 network: p53 and its downstream genes. Colloids Surf B Biointerfaces. 2007;55(1):10–8.PubMedCrossRef Shu KX, Li B, Wu LX. The p53 network: p53 and its downstream genes. Colloids Surf B Biointerfaces. 2007;55(1):10–8.PubMedCrossRef
9.
go back to reference Belda-Iniesta C, et al. Molecular biology of malignant gliomas. Clin Transl Oncol. 2006;8(9):635–41.PubMedCrossRef Belda-Iniesta C, et al. Molecular biology of malignant gliomas. Clin Transl Oncol. 2006;8(9):635–41.PubMedCrossRef
10.
go back to reference Somasundaram K, El-Deiry WS. Tumor suppressor p53 regulation and function. Front Biosci. 2000;5:d424–37.PubMedCrossRef Somasundaram K, El-Deiry WS. Tumor suppressor p53 regulation and function. Front Biosci. 2000;5:d424–37.PubMedCrossRef
11.
go back to reference Hoang-Xuan K, Idbaih A, Mokhtari K, Sanson M. Towards a molecular classification of gliomas. Bull Cancer. 2005;92(4):310–6. Review.PubMed Hoang-Xuan K, Idbaih A, Mokhtari K, Sanson M. Towards a molecular classification of gliomas. Bull Cancer. 2005;92(4):310–6. Review.PubMed
12.
go back to reference Pusztaszeri MP, Seelentag W, Bosman FT. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem. 2006;54(4):385–95.PubMedCrossRef Pusztaszeri MP, Seelentag W, Bosman FT. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem. 2006;54(4):385–95.PubMedCrossRef
13.
go back to reference Wang Y, Repyak K, Sheibani N. Expression pattern of alternatively spliced PECAM-1 isoforms in retinal vasculature. Mol Vis. 2004;10:103–7.PubMed Wang Y, Repyak K, Sheibani N. Expression pattern of alternatively spliced PECAM-1 isoforms in retinal vasculature. Mol Vis. 2004;10:103–7.PubMed
14.
go back to reference Wu J, Sheibani N. Modulation of VE-cadherin and PECAM-1 mediated cell-cell adhesions by mitogen-activated protein kinases. J Cell Biochem. 2003;90(1):121–37.PubMedCrossRef Wu J, Sheibani N. Modulation of VE-cadherin and PECAM-1 mediated cell-cell adhesions by mitogen-activated protein kinases. J Cell Biochem. 2003;90(1):121–37.PubMedCrossRef
15.
go back to reference Aroca F, Renaud W, Bartoli C, Bouvier-Labit C, Figarella-Branger D. Expression of PECAM-1/CD31 isoforms in human brain gliomas. J Neurooncol. 1999;43(2):19–25.PubMedCrossRef Aroca F, Renaud W, Bartoli C, Bouvier-Labit C, Figarella-Branger D. Expression of PECAM-1/CD31 isoforms in human brain gliomas. J Neurooncol. 1999;43(2):19–25.PubMedCrossRef
16.
go back to reference Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia, inducible factor-1. Genes Dev. 2000;14:34–44.PubMed Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia, inducible factor-1. Genes Dev. 2000;14:34–44.PubMed
17.
go back to reference Boenisch T. Formalin-fixed and heat-retrieved tissue antigens: a comparison of their immunoreactivity in experimental antibody diluents. Appl Immunohistochem Mol Morphol. 2001;9(2):176–9.PubMedCrossRef Boenisch T. Formalin-fixed and heat-retrieved tissue antigens: a comparison of their immunoreactivity in experimental antibody diluents. Appl Immunohistochem Mol Morphol. 2001;9(2):176–9.PubMedCrossRef
18.
go back to reference Louis DN, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.PubMedCrossRef Louis DN, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.PubMedCrossRef
19.
go back to reference Idbaih A, Omuro A, Ducray F, Hoang-Xuan K. Molecular genetic markers as predictors of response to chemotherapy in gliomas. Curr Opin Oncol. 2007;19(6):606–11. Review.PubMedCrossRef Idbaih A, Omuro A, Ducray F, Hoang-Xuan K. Molecular genetic markers as predictors of response to chemotherapy in gliomas. Curr Opin Oncol. 2007;19(6):606–11. Review.PubMedCrossRef
20.
go back to reference Ng H, Lo S, Huang D, Poon W. Paraffin section p53 protein immunohistochemistry in neuroectodermal tumors. Pathology. 1994;26(1):1–5.PubMedCrossRef Ng H, Lo S, Huang D, Poon W. Paraffin section p53 protein immunohistochemistry in neuroectodermal tumors. Pathology. 1994;26(1):1–5.PubMedCrossRef
21.
go back to reference Pollack IF, et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med. 2002;346(6):420–7.PubMedCrossRef Pollack IF, et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med. 2002;346(6):420–7.PubMedCrossRef
22.
go back to reference Sherwin R, Bozik M, Gollin S. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res. 1997;57(2):304–9.PubMed Sherwin R, Bozik M, Gollin S. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res. 1997;57(2):304–9.PubMed
23.
go back to reference Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H. Role of gemistocytes in astrocytoma progression. Lab Invest. 1997;76(6):277–82.PubMed Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H. Role of gemistocytes in astrocytoma progression. Lab Invest. 1997;76(6):277–82.PubMed
24.
go back to reference Kaur B, Brat DJ, Calkins CC, Van Meir EG. Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. Am J Pathol. 2003;162(1):19–27.PubMed Kaur B, Brat DJ, Calkins CC, Van Meir EG. Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. Am J Pathol. 2003;162(1):19–27.PubMed
25.
go back to reference Goldbrunner RH, et al. Vascularization of human glioma spheroids implanted into rat cortex is conferred by two distinct mechanisms. J Neurosci Res. 1999;55(4):486–95.PubMedCrossRef Goldbrunner RH, et al. Vascularization of human glioma spheroids implanted into rat cortex is conferred by two distinct mechanisms. J Neurosci Res. 1999;55(4):486–95.PubMedCrossRef
26.
go back to reference Assimakopoulou M, Sortiropoulou G, Maraziotis T, Papadakis N, Varakis I. Microvessel density in brain tumors. Anticancer Res. 1997;17:4747–53.PubMed Assimakopoulou M, Sortiropoulou G, Maraziotis T, Papadakis N, Varakis I. Microvessel density in brain tumors. Anticancer Res. 1997;17:4747–53.PubMed
27.
go back to reference Leon SP, Folkerth RD, Black P. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer. 1996;77(2):362–72.PubMedCrossRef Leon SP, Folkerth RD, Black P. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer. 1996;77(2):362–72.PubMedCrossRef
28.
go back to reference Abdulrauf SI, Edvardsen K, Ho KL, Yang XY, Rock JP. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low grade astrocytoma. J Neurosurg. 1998;88(3):513–20.PubMed Abdulrauf SI, Edvardsen K, Ho KL, Yang XY, Rock JP. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low grade astrocytoma. J Neurosurg. 1998;88(3):513–20.PubMed
Metadata
Title
Significance of p53 and CD31 in astrogliomas
Authors
Abdul-Zaher M. Khattab
Magdy I. Ahmed
Mohamed A. Fouad
Waleed A. Essa
Publication date
01-03-2009
Publisher
Humana Press Inc
Published in
Medical Oncology / Issue 1/2009
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-008-9094-7

Other articles of this Issue 1/2009

Medical Oncology 1/2009 Go to the issue